NHRI Enters Technology Transfer Agreement of DBPR215 with Jiayi Biomedical Co., Ltd.
National Health Research Institutes (NHRI) and Jia…
分類: News & Events
National Health Research Institutes Announces the Initiation of Phase I Clinical Trial of DBPR115, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
With budget supporting from Ministry of Economic A…
NHRI Enters Technology Transfer Agreement of DBPR211 with Applied Biopharma LLC, wholly owned by Agentix Corp. (AGTX) in the US
National Health Research Institutes (NHRI) and App…
Congratulations! Dr. Ta-Yuan Chang is elected as a member of the U.S. National Academy of Sciences.
We are honored to announce a good news that Profes…
A Safer Opioid Painkiller with Low Side-Effects─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine
The Ministry of Science and Technology has present…
Muscle age and lifespan: beyond physiological strength-NHRI has discovered a direct link between skeletal muscle aging and mortality through thermogenic and metabolic abnormalities
Using genetic modified mouse models, research at t…
NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp
The National Health Research Institutes (NHRI) and…
National Health Research Institutes Announces FDA approval of Investigational New Drug (IND) Applications for Two Novel Small Molecules, DBPR211 and DBPR114
Institute of Biotechnology and Pharmaceutical Rese…
DBPR211, a novel small-molecule anti-type 2 diabetes drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)
Institute of Biotechnology and Pharmaceutical Rese…
DBPR112, a novel small-molecule anticancer drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)
The Investigational New Drug (IND) application of …
National Health Research Institutes Announces the Initiation of Phase I Clinical Trial of DBPR115, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
With budget supporting from Ministry of Economic A…
NHRI Enters Technology Transfer Agreement of DBPR211 with Applied Biopharma LLC, wholly owned by Agentix Corp. (AGTX) in the US
National Health Research Institutes (NHRI) and App…
Congratulations! Dr. Ta-Yuan Chang is elected as a member of the U.S. National Academy of Sciences.
We are honored to announce a good news that Profes…
A Safer Opioid Painkiller with Low Side-Effects─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine
The Ministry of Science and Technology has present…
Muscle age and lifespan: beyond physiological strength-NHRI has discovered a direct link between skeletal muscle aging and mortality through thermogenic and metabolic abnormalities
Using genetic modified mouse models, research at t…
NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp
The National Health Research Institutes (NHRI) and…
National Health Research Institutes Announces FDA approval of Investigational New Drug (IND) Applications for Two Novel Small Molecules, DBPR211 and DBPR114
Institute of Biotechnology and Pharmaceutical Rese…
DBPR211, a novel small-molecule anti-type 2 diabetes drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)
Institute of Biotechnology and Pharmaceutical Rese…
DBPR112, a novel small-molecule anticancer drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)
The Investigational New Drug (IND) application of …